Autocrine/paracrine effects of FGF21 in rat cardiomyocytes.

Fig. 4A:FGF21 mRNA expression levels in cardiomyocytes following FGF21 (100 nM) treatment with or without pathway inhibitors [(U0126; wort (wortmanin); Comp C (Compound C) or TO (TO-901317)] (normalised to GAPDH and expressed as fold changes over basal).Fig. 4B: Graphical analysis of FGF21 protein levels following FGF21 treatment. Fig. 4C: Graphical representation of FGF21 ELISA measurements in the conditioned media following FGF21 treatment. Fig. 4D: Graphical representation of FGF21 ELISA measurements of rat heart Langendorff exudates following global ischemia for 5–30 mins and 120 mins of reperfusion; with or without prior FGF21 (100 nM) infusion. Data shown are means ± SEM of triplicates. The values represented are relative to basal. ***P<0.001; **P<0.01; *P<0.05 vs. FGF21 only treated, aP<0.001 vs. basal, n = 6 per group.